LONDON (AP) – AstraZeneca says advanced data from a US study of its COVID vaccine show that it is 79% effective.
Although the AstraZeneca vaccine has been approved in more than 50 countries, it has not yet received the green light in the United States. The U.S. study involved 30,000 volunteers, 20,000 of whom were vaccinated and the rest received fake shots. The results were announced on Monday.
In a statement, AstraZeneca says its COVID-19 vaccine is 79% effective in preventing symptomatic COVID և 100% effective in stopping serious illness և hospitalization. The researchers said that the vaccine was effective in all ages, including the elderly, which had not been confirmed by previous studies in other countries.
AstraZeneca should present the first findings of the US study to the Food and Drug Administration. The FDA Advisory Committee will publicly review the evidence behind the shooting before the agency decides to allow emergency use of the vaccine.
Scientists have been waiting for the results of the US study, hoping that it will remove some confusion about how well the staff actually works.
The UK first developed the vaccine based on partial trials in the United Kingdom, Brazil and South Africa, which showed that the shots were 70% effective. But those results were clouded by a production error that pushed some participants to get only half a dose on their first stroke. A mistake that the researchers did not immediately acknowledge.
Then came more questions about how well the vaccine protects older adults, and how long to wait until the second dose. Some European countries, including Germany, France, and Belgium, initially avoided firing on older people, changing their decisions only after new data suggested that it offered protection to seniors.
Last week, more than a dozen countries, mostly in Europe, temporarily stopped using the AstraZeneca shot after it was reported to be linked to blood clots. The European Medicines Agency concluded on Thursday that the vaccine did not increase the overall risk of blood clots, but could not rule out that it was linked to two very rare blood clots.
France, Germany, Italy and other countries later resumed use of the shot on Friday, with senior politicians raising their voices to show that the vaccine was safe.